Ovarian Carcinosarcoma Clinical Trials

20 clinical trials for Ovarian Carcinosarcoma across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer — RECRUITING · NA
• Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer — RECRUITING · PHASE3
• Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib — RECRUITING · PHASE2
• APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion — RECRUITING · PHASE2
• A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer — RECRUITING · PHASE1
• EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma — COMPLETED · PHASE2
• LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas — ACTIVE_NOT_RECRUITING · PHASE2
• MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer — TERMINATED · PHASE2
• Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) — COMPLETED · PHASE2
• Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers — COMPLETED · PHASE1
• The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors — TERMINATED · NA
• Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers — TERMINATED · PHASE1
• Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer — COMPLETED · PHASE1
• Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer — OTHER · PHASE3
• Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) — COMPLETED · PHASE1
• Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer — COMPLETED · PHASE2
• Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy — COMPLETED
• Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer — COMPLETED · PHASE2
• Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma — COMPLETED · PHASE2
• Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer — COMPLETED · PHASE1

Refine this search